Barusiban Subcutaneously for Reducing Implantation Failure Due to Uterine Contractions (the Basic Trial)

Sponsor: Ferring Pharmaceuticals

Investigators: A/Prof Luk Rombauts(1,2), Dr Alon Talmor (1), Dr Virochana Kaul (1), Dr Sameer Jatkar (1), Caroline Motteram (1), Deborah de Guingand (1)

1 Monash IVF, Clayton; 2 Monash Dept Obstetrics and Gynaecology

During a woman’s menstrual cycle, the muscular tissue in her womb contracts with different frequency. Contractions may also be induced when the fertilised egg(s) is transferred to the womb in women undergoing infertility treatment. Excessive contractions at the time of transferring the fertilised egg(s) have been associated with a reduced chance of pregnancy. It is hypothesised that these contractions expel the fertilised egg(s) from the womb or prevent it from implanting. A reduction in contractions in the womb on the day of transfer may thereby increase the chance of pregnancy in IVF/ICSI patients. Previous clinical trials have shown that Barusiban, a selective oxytocin antagonist, is able to reduce the frequency of contractions in the womb. This trial was the first using Ferring Pharmaceutical’s drug Barusiban in IVF/ICSI patients who had fertilised egg(s) transferred to the womb. The trial population included women with a history of several IVF/ICSI cycles that failed to result in a pregnancy. The trial aimed to determine the effect of Barusiban administered subcutaneously on the day of transfer on implantation and pregnancy rates in IVF/ICSI patients.

Recruitment for this project has now completed and the results are currently being prepared for publication.


  • This field is for validation purposes and should be left unchanged.
  • This field is for validation purposes and should be left unchanged.